← Back to Search

Farnesyl Transferase Inhibitor

R115777 + Topotecan for Cancer

Phase 1

Waitlist Available

Research Sponsored by National Center for Research Resources (NCRR)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Radiotherapy to less than 25% of bone marrow volume (no pelvic radiation)

Recovery from the effects of prior chemotherapy and radiation therapy, with at least a 4 week interval. All prior toxicities should have resolved to baseline prior to entry into the study

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is designed to find the maximum tolerated dose of the combination of R115777 and topotecan in patients with advanced solid tumors.

Who is the study for?

This trial is for adults with advanced solid tumors who've had less than four chemo treatments and no recent infections. They should be in good health otherwise, not pregnant or breastfeeding, willing to use birth control, and have a life expectancy of at least six months. They must also have recovered from any previous treatments.Check my eligibility

What is being tested?

The study tests combining R115777, which may block cancer growth by targeting the p21 ras gene, with topotecan that attacks cells ignoring normal growth controls. This mix could work better together and R115777 can be taken orally.See study design

What are the potential side effects?

Potential side effects include those common to chemotherapy such as nausea, fatigue, hair loss, blood cell count changes increasing infection risk; specific effects of R115777 are not detailed but may involve organ function issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have received radiation that did not cover more than 25% of my bone marrow and did not include my pelvis.

Select...

I have recovered from my last cancer treatment and it's been at least 4 weeks.

Select...

I do not have stomach or intestine problems affecting medication absorption.

Select...

I have had 3 or fewer chemotherapy treatments.

Select...

I have not been on medication for an infection in the week before starting chemotherapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Center for Research Resources (NCRR)Lead Sponsor

537 Previous Clinical Trials

317,016 Total Patients Enrolled

Media Library

R115777 (Farnesyl Transferase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00006199 — Phase 1

Cancer Clinical Trial 2023: R115777 Highlights & Side Effects. Trial Name: NCT00006199 — Phase 1

R115777 (Farnesyl Transferase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006199 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How reliable is this therapy for providing a desirable outcome?

"Minimal clinical evidence exists to support the safety and efficacy of this treatment, which earns it a score of 1."

Answered by AI

Is this experiment accepting individuals who are 45 years of age or older?

"This trial's inclusion criteria stipulates that participants must be of adult age (18+ years old) and not exceed the maximum age threshold (65 years or younger)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)

2024. "Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00006199.

All > New York